{"id":863,"date":"2020-12-06T16:32:42","date_gmt":"2020-12-06T16:32:42","guid":{"rendered":"http:\/\/crosscatapultn.wpengine.com\/?post_type=case_study&p=863"},"modified":"2022-10-13T09:28:44","modified_gmt":"2022-10-13T08:28:44","slug":"pioneering-technology-to-increase-effectiveness-of-gene-therapeutics","status":"publish","type":"case_study","link":"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/","title":{"rendered":"Pioneering technology to increase effectiveness of gene therapeutics"},"content":{"rendered":"
\n\n
CASE STUDY<\/span>

Pioneering technology to increase effectiveness of gene therapeutics<\/h2> <\/div>

A collaboration between the Cell and Gene Therapy Catapult and Synpromics set out to develop novel scalable manufacturing processes and technologies to produce viral vectors at scale. <\/p> <\/div> <\/div>\n \n

\n
\n \n <\/div>\n <\/div> <\/div>\n\n <\/div>\n\n\n
<\/div>\n\n\n\n
\n
\n \n <\/span>\n\n \n\n
\n Synpromics acquired by AskBio in August 2019\n <\/div>\n\n <\/div>\n\n
<\/div>\n\n <\/div>
\n \n <\/span>\n\n \n\n
\n \n <\/div> <\/div>\n\n
<\/div>\n\n <\/div>\n\n <\/div> <\/div>\n\n <\/div><\/div>\n\n\n\n
\n \n \n <\/svg>\n

\n We believe Synpromics\u2019 technology will provide a critically needed solution to high titre, industrial scale, vector manufacture, a critical barrier in the gene therapy industry. The result of this solution will be a major advance to the commercialisation of gene therapies<\/em> <\/p>\n \n

\n Dr David Venables<\/strong>
CEO of Synpromics <\/div>\n \n \n
\n \n \n <\/svg>\n <\/div>\n <\/div>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n

Bridging the gap between scientific research and commercialisation<\/h2>\n\n\n\n
<\/div>\n\n\n\n

Scotland based SME Synpromics, is a market leader in the development of synthetic DNA sequences for gene control, a technology which allows for genes to be switched on and off. A collaboration between the Cell and Gene Therapy Catapult and Synpromics set out to develop novel scalable manufacturing processes and technologies to produce viral vectors at scale. <\/p>\n\n\n\n

Viral vectors are tools commonly used by molecular biologists<\/a> to deliver genetic material<\/a> into cells<\/a>. They are a critical component in the development of many cell and gene therapies and have been employed for the treatment of various diseases such as cardiovascular, muscular, hematologic, ophthalmologic, and infectious diseases and different types of cancer. <\/p>\n<\/div>\n\n\n\n

\n
\"\"<\/figure>\n<\/div>\n<\/div>\n\n\n\n

A lack of solutions for the large-scale manufacture of viral vectors together with their high cost, are well-recognised barriers to the growth of the cell and gene therapy industry globally. <\/p>\n\n\n\n

Increasing the productivity and reducing cost of viral vector manufacture would create significant benefits to the wider cell and gene therapy industry as well as research institutes and ultimately for patients.<\/p>\n\n\n\n

The infrastructure and expertise within the Cell and Gene Therapy Catapult was pivotal to developing new novel analytical assays for adeno-associated viral vectors and lentiviral vector manufacture. The Cell and Gene Therapy Catapult was able to help demonstrate Synpromics as an exemplar in viral vector manufacturing processes which led to their acquisition by AskBio in August 2019 to expand their gene therapy technology portfolio.<\/p>\n\n\n\n

Enhancing Synpromics\u2019 capabilities for qualifying cell lines to produce viral vectors, the Cell and Gene Therapy Catapult helped to consolidate the company\u2019s position as an industry leader. Synpromics now operates as a wholly owned subsidiary and is headquartered in Edinburgh, United Kingdom. The combined expertise of Synpromics and AskBio will better enable them to develop potentially life-changing cell and gene therapies for diseases with an unmet medical need.<\/p>\n\n\n\n

<\/div>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

A collaboration between the Cell and Gene Therapy Catapult and Synpromics set out to develop novel scalable manufacturing processes and technologies to produce viral vectors at scale. <\/p>\n","protected":false},"featured_media":999,"template":"","meta":{"_external_link_checkbox":false,"_external_link":"","_event_date":"","_featured_case_study":false},"categories":[9],"tags":[15,16],"class_list":["post-863","case_study","type-case_study","status-publish","has-post-thumbnail","hentry","category-cell-and-gene-therapy","tag-modernising-health","tag-accelerating-business-growth"],"yoast_head":"\nPioneering technology to increase effectiveness of gene therapeutics - The Catapult Network<\/title>\n<meta name=\"description\" content=\"A collaboration between the Cell and Gene Therapy Catapult and Synpromics set out to develop novel scalable manufacturing processes and technologies to produce viral vectors at scale.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pioneering technology to increase effectiveness of gene therapeutics - The Catapult Network\" \/>\n<meta property=\"og:description\" content=\"A collaboration between the Cell and Gene Therapy Catapult and Synpromics set out to develop novel scalable manufacturing processes and technologies to produce viral vectors at scale.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"The Catapult Network\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-13T08:28:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2020\/12\/CGTC.png\" \/>\n\t<meta property=\"og:image:width\" content=\"562\" \/>\n\t<meta property=\"og:image:height\" content=\"465\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@Catapult_UK\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/\",\"url\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/\",\"name\":\"Pioneering technology to increase effectiveness of gene therapeutics - The Catapult Network\",\"isPartOf\":{\"@id\":\"https:\/\/catapult.org.uk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2020\/12\/CGTC.png\",\"datePublished\":\"2020-12-06T16:32:42+00:00\",\"dateModified\":\"2022-10-13T08:28:44+00:00\",\"description\":\"A collaboration between the Cell and Gene Therapy Catapult and Synpromics set out to develop novel scalable manufacturing processes and technologies to produce viral vectors at scale.\",\"breadcrumb\":{\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/#primaryimage\",\"url\":\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2020\/12\/CGTC.png\",\"contentUrl\":\"https:\/\/catapult.org.uk\/wp-content\/uploads\/2020\/12\/CGTC.png\",\"width\":\"562\",\"height\":\"465\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/catapult.org.uk\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Case Studies\",\"item\":\"https:\/\/catapult.org.uk\/our-work\/case-studies\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Pioneering technology to increase effectiveness of gene therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/catapult.org.uk\/#website\",\"url\":\"https:\/\/catapult.org.uk\/\",\"name\":\"The Catapult Network\",\"description\":\"The Innovate UK Catapult Network\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/catapult.org.uk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pioneering technology to increase effectiveness of gene therapeutics - The Catapult Network","description":"A collaboration between the Cell and Gene Therapy Catapult and Synpromics set out to develop novel scalable manufacturing processes and technologies to produce viral vectors at scale.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/","og_locale":"en_GB","og_type":"article","og_title":"Pioneering technology to increase effectiveness of gene therapeutics - The Catapult Network","og_description":"A collaboration between the Cell and Gene Therapy Catapult and Synpromics set out to develop novel scalable manufacturing processes and technologies to produce viral vectors at scale.","og_url":"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/","og_site_name":"The Catapult Network","article_modified_time":"2022-10-13T08:28:44+00:00","og_image":[{"width":562,"height":465,"url":"https:\/\/catapult.org.uk\/wp-content\/uploads\/2020\/12\/CGTC.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@Catapult_UK","twitter_misc":{"Estimated reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/","url":"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/","name":"Pioneering technology to increase effectiveness of gene therapeutics - The Catapult Network","isPartOf":{"@id":"https:\/\/catapult.org.uk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/catapult.org.uk\/wp-content\/uploads\/2020\/12\/CGTC.png","datePublished":"2020-12-06T16:32:42+00:00","dateModified":"2022-10-13T08:28:44+00:00","description":"A collaboration between the Cell and Gene Therapy Catapult and Synpromics set out to develop novel scalable manufacturing processes and technologies to produce viral vectors at scale.","breadcrumb":{"@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/#primaryimage","url":"https:\/\/catapult.org.uk\/wp-content\/uploads\/2020\/12\/CGTC.png","contentUrl":"https:\/\/catapult.org.uk\/wp-content\/uploads\/2020\/12\/CGTC.png","width":"562","height":"465"},{"@type":"BreadcrumbList","@id":"https:\/\/catapult.org.uk\/our-work\/case-studies\/pioneering-technology-to-increase-effectiveness-of-gene-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/catapult.org.uk\/"},{"@type":"ListItem","position":2,"name":"Case Studies","item":"https:\/\/catapult.org.uk\/our-work\/case-studies\/"},{"@type":"ListItem","position":3,"name":"Pioneering technology to increase effectiveness of gene therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/catapult.org.uk\/#website","url":"https:\/\/catapult.org.uk\/","name":"The Catapult Network","description":"The Innovate UK Catapult Network","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/catapult.org.uk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/case_study\/863","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/types\/case_study"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/media\/999"}],"wp:attachment":[{"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/media?parent=863"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/categories?post=863"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/catapult.org.uk\/wp-json\/wp\/v2\/tags?post=863"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}